New eye drug PRO-169 takes on standard treatment for Diabetes-Related vision loss
NCT ID NCT05217680
First seen Mar 16, 2026 · Last updated May 16, 2026 · Updated 12 times
Summary
This study tested a new eye medication called PRO-169 against a standard treatment (ranibizumab) for diabetic macular edema, a condition that causes vision loss in people with diabetes. 510 adults with diabetes received injections into the eye over one year. The goal was to see if PRO-169 works as well as the standard drug at improving vision. The study is complete, and results will show if PRO-169 is a safe and effective alternative.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIABETIC MACULAR EDEMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
SalaUno Salud, S.A.P.I. de C.V.
Mexico City, 06030, Mexico
Conditions
Explore the condition pages connected to this study.